The differential usage of molecular machinery in brain cancer patients with iron-enriched glioma environments

<p>Gliomas are neuroepithelial tumors in the brain or spinal cord that arise from glial or precursor cells and include astrocytomas, oligodendrogliomas, and ependymomas. They are the most common malignant primary central nervous system tumors, representing 75% of cases in adults and 24% of all...

Full description

Saved in:
Bibliographic Details
Main Authors: Brandon Lucke-Wold (Author), Michael Joseph Diaz (Author), Joanna Song (Author), Sai Batchu (Author), Kevin Root (Author), Karan Patel (Author), Kamil Taneja (Author)
Format: Book
Published: Journal of Surgery and Surgical Research - Peertechz Publications, 2022-09-26.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 peertech__10_17352_2455-2968_000150
042 |a dc 
100 1 0 |a Brandon Lucke-Wold  |e author 
700 1 0 |a  Michael Joseph Diaz  |e author 
700 1 0 |a  Joanna Song  |e author 
700 1 0 |a  Sai Batchu  |e author 
700 1 0 |a  Kevin Root  |e author 
700 1 0 |a  Karan Patel  |e author 
700 1 0 |a Kamil Taneja  |e author 
245 0 0 |a The differential usage of molecular machinery in brain cancer patients with iron-enriched glioma environments 
260 |b Journal of Surgery and Surgical Research - Peertechz Publications,   |c 2022-09-26. 
520 |a <p>Gliomas are neuroepithelial tumors in the brain or spinal cord that arise from glial or precursor cells and include astrocytomas, oligodendrogliomas, and ependymomas. They are the most common malignant primary central nervous system tumors, representing 75% of cases in adults and 24% of all cases of primary brain and CNS tumors [1,2]. Despite radiotherapy and temozolomide chemotherapy, which are the current gold-standard first-line treatments, patients with gliomas, particularly the highly aggressive and most common subtype glioblastoma multiforme, still have a poor prognosis with a median survival time of 15 months and 5-year survival rates of 5% [3-6]. </p> 
540 |a Copyright © Brandon Lucke-Wold et al. 
546 |a en 
655 7 |a Research Article  |2 local 
856 4 1 |u https://doi.org/10.17352/2455-2968.000150  |z Connect to this object online.